Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders.
The last earnings update was 46 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Rhythm Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Rhythm Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Rhythm Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Rhythm Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Rhythm Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Rhythm Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Rhythm Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Rhythm Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Rhythm Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Rhythm Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Keith Michael Gottesdiener, M.D. has been the Chief Executive Officer of Rhythm Holding Company, LLC since October 2011. Dr. Gottesdiener has been the Chief Executive Officer of Rhythm Pharmaceuticals Inc. since October 2011 and has been its President since August 2017. He joined Rhythm after 16 years at Merck Research Laboratories, or Merck. Prior to Rhythm, he served as Vice President and Late-Stage Therapeutic Group Leader at Merck & Co., Inc., with responsibility for pivotal trials of Merck's products in all therapeutic areas and served as the Head of Early-Stage Clinical Development Programs. Over a 16-year career at Merck, he was responsible for more than 40 major clinical programs and products, including the approval of Gardasil(TM) (HPV vaccine) and the more recent FDA approval of Victrelis(TM) (HCV protease inhibitor). From 2006 to 2011, he was a Leader of Merck’s late clinical development organization, first overseeing the development of Merck’s infectious diseases and vaccine products through pivotal trials, registration and life cycle management, including GardasilTM (HPV Vaccine), RotateqTM (rotavirus vaccine), ZostavaxTM (zoster vaccine) and IsentressTM (HIV integrase inhibitor), among others. In 2008, Dr. Gottesdiener was appointed Late Stage Therapeutic Group Leader, and in that role led Merck’s late-stage clinical development efforts (from Phase 2 through patent expiry) across all therapeutic areas. After Merck’s merger with Schering-Plough Corporation in 2009, he continued as Co-Head of Late Development. From 2009 to 2011, he served as Merck’s Vice President of Clinical Sciences and Therapeutic Area Group Leader. Dr. Gottesdiener was the Chief Executive Officer of Motus Therapeutics, Inc. since October 2011 until December 2016. He has been a Director of Intercept Pharmaceuticals, Inc. since July 19, 2016. He served as the Chairman at Rhythm Pharmaceuticals, Inc. until April 2017 and has been its Director since October 2011. He has extensive experience in the pharmaceutical industry as a senior executive. Dr. Gottesdiener joined Merck in 1995 and held positions of increasing responsibility, eventually leading Merck's early clinical development across all therapeutic areas from 2001 through early 2006. Dr. Gottesdiener served as the Chairman of Motus Therapeutics, Inc. and served as its Director until December 2016. He served as the Chairman of the Board of Rhythm Holding Company, LLC until April 2017 and has been its Director since October 2011. After his fellowship, he did Postdoctoral Research in the Laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor. In 1986, he joined the faculty as an Assistant Professor at Columbia University, started an independent research laboratory with NIH RO-1 funding, focusing on gene transcription and was Associate Clinical Professor of Medicine at the time he left to enter Merck in 1995. He completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs. Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania.
Keith's compensation has increased whilst company is loss making.
Keith's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Rhythm Pharmaceuticals management team is less than 2 years, this suggests a new team.
CFO & Treasurer
Chief Commercial Officer
Lex van der Ploeg
Chief Scientific Officer
Chief Human Resources Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Rhythm Pharmaceuticals board of directors is about average.
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company’s lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.